About Us

Insmed Press Releases

NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule

December 16, 2010

Insmed Announces Podium Presentation at the Pediatric Academic Societies’ 2006 Annual Meeting

April 26, 2006

NORD Honors Insmed for Role in Developing Treatments for Rare Diseases

April 26, 2006

Insmed Announces Additional Information in Compliance with NASDAQ Rules

March 22, 2006

Insmed Completes $46 Million Public Offering; Underwriters Exercise In Full Option to Purchase Additional Shares

March 15, 2006

Insmed Prices $40 Million Equity Offering

March 10, 2006

Insmed Incorporated Announces Proposed Public Offering of Common Stock

March 6, 2006

Insmed to Announce 2005 Fourth Quarter and Year End Financial Results; Thursday, March 2

February 23, 2006

U. of Rochester Initiates Phase 2 Clinical Trial of Insmed’s iPlex for the Treatment of Myotonic Muscular Dystrophy; Trial Funded by NIH and MDA Grants

January 4, 2006

FDA Approves Insmed’s Orphan Drug, IPLEX, for the Treatment of Severe Primary IGF-1 Deficiency; The First Once-Daily Therapy for the Treatment of Severe Primary IFG-1 Deficiency

December 12, 2005

Press Releases

May. 16, 2012
Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman Read More
May. 8, 2012
Insmed Announces First Quarter 2012 Financial Results Read More